Form 4: Sarepta Therapeutics Director M. Kathleen Behrens Reports Acquisition of Shares and Stock Options

Director M. Kathleen Behrens reports acquisition of common stock and stock options in Sarepta Therapeutics.

Summary

• On March 10, 2025, M. Kathleen Behrens, a director of Sarepta Therapeutics, acquired 2,383 shares of common stock through restricted stock units (RSUs).
• These RSUs will vest in full on March 10, 2026.
• Behrens also acquired stock options for 4,792 shares of common stock at an exercise price of $99.69, exercisable from March 10, 2026, to March 10, 2035.
• Following these transactions, Behrens directly owns 193,476 shares of common stock and indirectly owns 10,000 shares through a trust.
• She also directly owns options for 4,792 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying can be interpreted as a sign of confidence, but it's a routine transaction.

Positives

• The acquisition of shares and stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, which can be informative for investors.

Stakeholder Impact

• The acquisition of shares and stock options by a director may have a slightly positive impact on shareholder sentiment.

Key Dates